The 5th WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials, 12-13 February 2009, Geneva
Presentations
WHO disclaimer:
The designations employed and the presentation of the material on the web only represents the views of the authors and do not imply the expression of any opinion whatsoever on the part of the World Health organization concerning the legal status of any country, territory, city or area or of its authorities.
The World Health organization does not warrant that the information contained in this material is complete and correct and shall not be liable for any damages incurred as a result of its use.
The following documents are listed according to the agenda order of the presenters.
-
Further studies on an alum-adjuvanted H5N1 candidate vaccine, CSL Australia - T. Nolan
pdf, 2.29Mb -
Update on H5N1 vaccine, Sinovac Biotech., China - Y. Zou
pdf, 1.50Mb -
Update on H5N1 vaccine, Sanofi Pasteur - M. Denis
pdf, 2.02Mb -
Update on H5N1 vaccine, GSK Biologicals - E. Hanon
pdf, 1.44Mb -
Update from the NIH on inactivated vaccine trials - L. Lambert
pdf, 216kb -
Update on H5N1 vaccine, Baxter - O. Kistner
pdf, 163kb -
Safety and immunogenicity of the cell- derived whole virus H5N1 vaccine in the phase 1 trial, Vabiotech, Vietnam - N. Thu Van
pdf, 308kb -
Live attenuated pandemic influenza vaccines: preclinical data - C. Luke
pdf, 306kb -
Live attenuated pandemic influenza H2N2 and H6N1 vaccines: clinical data - K. Talaat
pdf, 719kb -
H5N2 in Phase II clinical trials, Microgen and Inst. Exp. Medicine, Russia - V. Zverev
pdf, 721kb -
Evaluation of DelNS1 intranasal H5N1 vaccine - J. Romanova
pdf, 1.26Mb -
Safety and immunogenicity of an H5N1 (A/Indonesia/05/2005) virus-like particle vaccine candidate, Novavax, USA - P. Heaton
pdf, 4.58Mb -
Development of split virosomal pre-pandemic influenza vaccine adjuvanted with Aluminum Hydroxide, Microgen, Russia - I. Krasilnikov
pdf, 478kb -
Phase 1 safety and immunogenicity results of Vaxfectin-formulated influenza H5 DNA vaccines, Vical, USA - L. Smith
pdf, 2.44Mb -
PhaseI/II clinical trials of rHA protein of H5N1, UMN Pharma, Japan - S. Kanazashi
pdf, 373kb -
Results of Different H5N1 Vaccine - Adjuvant Studies - R. Robinson
pdf, 409kb -
Update on development of international standards for H5N1 antibodies - J. Wood
pdf, 284kb -
Novel methods for assessment of immunogenicity of pandemic vaccines - K. Hoschler
pdf, 1.09Mb -
Progress in regulatory preparedness - D. Wood
pdf, 278kb
Last updated: 6 April 2009